Seither R L, Trent D F, Mikulecky D C, Rape T J, Goldman I D
Department of Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298.
J Biol Chem. 1991 Mar 5;266(7):4112-8.
An important unresolved issue in antifolate pharmacology is the basis for the observation that the major portion of cellular tetrahydrofolate cofactors is preserved after dihydrofolate reductase activity is abolished by antifolates despite the fact that tetrahydrofolate cofactor-dependent purine and pyrimidine biosynthesis ceases. This has been attributed to feedback inhibition of thymidylate synthase by dihydrofolate polyglutamates that accumulate in the presence of antifolates. This report combines network thermodynamic modeling and experimental observations to evaluate the effects of direct inhibition of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site with a potent lipophilic quinazoline antifolate PD130883 on folate oxidation in cells. Computer simulations predict and the data indicate that marked PD130883 suppression of thymidylate synthase only slows the rate but not the extent of tetrahydrofolate cofactor interconversion to dihydrofolate upon complete suppression of dihydrofolate reductase with trimetrexate. These observations are consistent with earlier studies from this laboratory with fluorodeoxyuridine inhibition at the deoxyuridylate binding site. Hence, the much weaker inhibition by dihydrofolate polyglutamates at the level of thymidylate synthase cannot account for the apparent preservation of tetrahydrofolate cofactor pools in cells and has virtually no pharmacologic significance under conditions in which antifolates completely suppress dihydrofolate reductase. The extent of interconversion of tetrahydrofolate cofactors to dihydrofolate is strongly influenced by residual dihydrofolate reductase catalytic activity. Exposure of cells to 0.1 microM trimetrexate results in only approximately 60% of maximum dihydrofolate levels achieved when dihydrofolate reductase activity is abolished. Network thermodynamic simulations predict, and experiments verify, that inhibition of thymidylate synthase at the 5,10-methylenetetrahydrofolate site by PD130883, when dihydrofolate reductase is only partially suppressed (approximately 85%) with 0.1 microM trimetrexate, substantially decreases (31-47%) the net level of interconversion of tetrahydrofolate cofactors to dihydrofolate. Further computer simulations predict that under conditions in which residual dihydrofolate reductase activity persists within the cells (more than about 5%), feedback inhibitory effects of dihydrofolate polyglutamates as well as other weak inhibitors of thymidylate synthase can significantly limit the extent of net interconversion of tetrahydrofolate cofactors to dihydrofolate and produce an apparent "compartmentation phenomenon" in which tetrahydrofolate cofactor pools are preserved within the cell in the presence of antifolates. Residual dihydrofolate reductase activity cannot, however, account for the partial interconversion of tetrahydrofolate cofactors to dihydrofolate after exposure to high trimetrexate or methotrexate levels.(ABSTRACT TRUNCATED AT 400 WORDS)
抗叶酸药理学中一个重要的未解决问题是,尽管抗叶酸药物使二氢叶酸还原酶活性丧失后,细胞内四氢叶酸辅因子的大部分得以保留,而依赖四氢叶酸辅因子的嘌呤和嘧啶生物合成却停止了。这被归因于抗叶酸药物存在时积累的二氢叶酸多聚谷氨酸对胸苷酸合成酶的反馈抑制。本报告结合网络热力学建模和实验观察,以评估在5,10 - 亚甲基四氢叶酸结合位点用强效亲脂性喹唑啉抗叶酸药物PD130883直接抑制胸苷酸合成酶对细胞中叶酸氧化的影响。计算机模拟预测且数据表明,在用三甲曲沙完全抑制二氢叶酸还原酶后,PD130883对胸苷酸合成酶的显著抑制仅减缓了四氢叶酸辅因子向二氢叶酸转化的速率,而非程度。这些观察结果与本实验室早期关于氟脱氧尿苷在脱氧尿苷酸结合位点抑制的研究一致。因此,二氢叶酸多聚谷氨酸在胸苷酸合成酶水平上的较弱抑制无法解释细胞中四氢叶酸辅因子池的明显保留,并且在抗叶酸药物完全抑制二氢叶酸还原酶的条件下几乎没有药理学意义。四氢叶酸辅因子向二氢叶酸的转化程度受残余二氢叶酸还原酶催化活性的强烈影响。细胞暴露于0.1微摩尔/升三甲曲沙时,二氢叶酸还原酶活性被消除后所达到的最大二氢叶酸水平仅约为60%。网络热力学模拟预测且实验验证,当用0.1微摩尔/升三甲曲沙仅部分抑制(约85%)二氢叶酸还原酶时,PD130883在5,10 - 亚甲基四氢叶酸位点对胸苷酸合成酶的抑制会显著降低(31 - 47%)四氢叶酸辅因子向二氢叶酸的净转化水平。进一步的计算机模拟预测,在细胞内存在残余二氢叶酸还原酶活性(超过约5%)的条件下,二氢叶酸多聚谷氨酸以及胸苷酸合成酶的其他弱抑制剂的反馈抑制作用可显著限制四氢叶酸辅因子向二氢叶酸的净转化程度,并产生一种明显的“分隔现象”,即在抗叶酸药物存在的情况下,细胞内的四氢叶酸辅因子池得以保留。然而,残余的二氢叶酸还原酶活性无法解释在暴露于高剂量三甲曲沙或甲氨蝶呤后四氢叶酸辅因子向二氢叶酸的部分转化。(摘要截选至400字)